The Psychedelic Skeptic
After Matthew Perry's tragic death raised new questions about ketamine therapy, Sam Mandel, CEO of Ketamine Clinics Los Angeles, joins us to separate fact from fiction. With over 30,000 infusions administered and an 83% success rate, KCLA is at the forefront of mental health innovation. Sam breaks down: * The crucial differences between recreational use and clinical treatment * Why ketamine remains the fastest-acting antidepressant available * How supervised infusion therapy actually works * The future of ketamine alongside other psychedelic treatments * Common misconceptions and stigma around ketamine therapy This episode offers a clear-eyed look at ketamine's therapeutic potential while acknowledging valid concerns about its use. Whether you're considering treatment or just curious about developments in mental health care, this conversation provides essential context from one of the field's leading voices.
22 Folgen
Kommentare
0Sei die erste Person, die kommentiert
Melde dich jetzt an und werde Teil der The Psychedelic Skeptic-Community!